Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial

References

• Available from: http://www.who.int/en/news-room/fact-sheets/detail/household-air-pollution-and-health. Accessed 15, 2019.
   Google Scholar
• Gordon SB, Bruce NG, Grigg J, et al. Respiratory risks from household air pollution in low and middle-income countries. Lancet Respir Med. 2014;2(10):823–860. doi:10.1016/S2213-2600(14)70168-725193349
   PubMed Web of Science ®Google Scholar
• Balmes JR. When smoke gets in your lungs. Proc Am Thorac Soc. 2010;7(2):98–101. doi:10.1513/pats.200907-081RM20427578
   PubMedGoogle Scholar
• Armstrong JR, Campbell H. Indoor air pollution exposure and lower respiratory infections in young Gambian children. Int J Epidemiol. 1991;20(2):424–429. doi:10.1093/ije/20.2.4241917245
   PubMed Web of Science ®Google Scholar
• Sood A, Assad NA, Barnes PJ, et al. ERS/ATS workshop report on respiratory health effects of household air pollution. Eur Respir J. 2018;51:1700698. doi:10.1183/13993003.00698-201729301918
   PubMed Web of Science ®Google Scholar
• Naeher LP, Brauer M, Lipsett M, et al. Woodsmoke health effects: a review. Inhal Toxicol. 2007;19(1):67–106. doi:10.1080/08958370600985875
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, Schilmann A, Riojas-Rodriguez H. Respiratory health effects of indoor air pollution. Int J Tuberc Lung Dis. 2010;14(9):1079–1086.20819250
   PubMed Web of Science ®Google Scholar
• Available from: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Last. Accessed 15, 2019.
   Google Scholar
• Montes de Oca M, López Varela MV, Acuña A, et al. ALAT-2014 Chronic obstructive pulmonary disease (COPD) clinical practice guidelines: questions and answers. Arch Bronconeumol. 2015;51(8):403–416. doi:10.1016/j.arbres.2014.11.01725596991
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103. [PubMed]. doi:10.1056/NEJMoa100837821428765
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. doi:10.1016/S2213-2600(13)70052-324429126
   PubMed Web of Science ®Google Scholar
• Littner MR, Ilowite JS, Tashkin DP Jr, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1136–1142. doi:10.1164/ajrccm.161.4.990304410764302
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102(7):1033–1044. doi:10.1016/j.rmed.2008.02.00118479895
   PubMed Web of Science ®Google Scholar
• Rossi A, Polese G. Indacaterol: a comprehensive review. Int J Chron Obstruct Pulmon Dis. 2013;8:353–363. doi:10.2147/COPD.S2162523922496
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. doi:10.1183/09031936.04.0011600415218994
   PubMed Web of Science ®Google Scholar
• Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease–a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med. 2014;4(14):158. doi:10.1186/1471-2466-14-158
   Web of Science ®Google Scholar
• Cazzola M, Biscione GL, Pasqua F, et al. Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD. Respir Med. 2008;102:1425–1430. doi:10.1016/j.rmed.2008.04.01718621519
   PubMed Web of Science ®Google Scholar
• Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1447–1478. doi:10.1183/09031936.0000381425359356
   PubMed Web of Science ®Google Scholar
• Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47:429–460. doi:10.1183/13993003.00745-201526797036
   PubMed Web of Science ®Google Scholar
• Spruit MA, Polkey MI, Celli B, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Predicting outcomes from 6 min walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2012;13(3):291–297. doi:10.1016/j.jamda.2011.06.00921778120
   PubMed Web of Science ®Google Scholar
• O´Donnell DE. Hyperinflation dyspnea and exercise intolerance in chonic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–184. doi:10.1513/pats.200508-093DO16565429
   PubMedGoogle Scholar
• Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–1446. doi:10.1183/09031936.0000381425359355
   PubMed Web of Science ®Google Scholar
• Pérez-Padilla R. Population distribution residing at different altitudes: implications for hypoxemia. Arch Med Res. 2002;33(2):162–166.11886716
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, Regalado J, Vedal S, et al. Exposure to biomass smoke and chronic airway disease in Mexican women: a case-control study. Am J Respir Crit Care Med. 1996;154:701–706. doi:10.1164/ajrccm.154.3.88106088810608
   PubMed Web of Science ®Google Scholar
• Ramírez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med. 2014;190(9):996–1002. doi:10.1164/rccm.201404-0720OC25172140
   PubMed Web of Science ®Google Scholar
• Ramírez-Venegas A, Sansores RH, Pérez-Padilla R, et al. Survival of patients with chronic obstructive pulmonary disease due to biomass smoke and tobacco. Am J Respir Crit Care Med. 2006;173(4):393–397. doi:10.1164/rccm.200504-568OC16322646
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, Regalado J, Vazquez Garcıa JC. Reproducibilidad espirometrica y adecuacion a valores de referencia internacionales en trabajadores Mexicanos demandando incapacidad. Salud Publica Mex. 2001;43:113–121. doi:10.1590/S0036-3634200100020000611381840
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179–187. doi:10.1164/ajrccm.159.1.97121089872837
   PubMed Web of Science ®Google Scholar
• Tantucci C, Pinelli V, Cossi S, Guerini M, Donato F, Grassi V; SARA Study Group. Reference values and repeatability of inspiratory capacity for men and women aged 65-85. Respir Med. 2006;100(5):871–877. doi:10.1016/j.rmed.2005.08.01716203126
   PubMed Web of Science ®Google Scholar
• ATS statement: guidelines for the six-minute walk test. ATS committee on proficiency standards for clinical pulmonary function laboratories. Am J Respir Crit Care Med. 2002;166(1):111–173. doi:10.1164/ajrccm.166.1.at110212091180
   PubMed Web of Science ®Google Scholar
• Zutler M, Singer JP, Omachi TA, et al. Relationship of obesity with respiratory symptoms and decreased functional capacity in adults without established COPD. Prim Care Respir J. 2012;21(2):194–201. doi:10.4104/pcrj.2012.0002822453663
   PubMedGoogle Scholar
• Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6 min-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1395–1399. doi:10.1164/ajrccm.163.6.200317211371407
   PubMed Web of Science ®Google Scholar
• Bédard ME, Brouillard C, Pepin V, et al. Tiotropium improves walking endurance in COPD. Eur Respir J. 2012;39(2):265–271. doi:10.1183/09031936.0005951121700602
   PubMed Web of Science ®Google Scholar
• Fernandes FL, Pavezi VA, Dias SA Jr, Pinto RM, Stelmach R, Cukier A. Short-term effect of tiotropium in COPD patients being treated with a beta2 agonist]. J Bras Pneumol. 2010;36(2):181–189. doi:10.1590/S1806-3713201000020000520485938
   PubMed Web of Science ®Google Scholar
• Jayaram L, Wong C, McAuley S, Rea H, Zeng I, O’Dochartaigh C. Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6 min walk test. COPD. 2013;10(4):466–472. doi:10.3109/15412555.2013.77116223875741
   PubMedGoogle Scholar
• Celli B, Tetzlaff K, Criner G, et al; COPD Biomarker Qualification Consortium. The 6 min-walk distance test as a chronic obstructive pulmonary disease stratification tool. Insights from the COPD biomarker qualification consortium. Am J Respir Crit Care Med. 2016;194(12):1483–1493. doi:10.1164/rccm.201508-1653OC27332504
   PubMed Web of Science ®Google Scholar
• Pérez-Padilla R, Ramirez-Venegas A, Sansores-Martinez R. Clinical characteristics of patients with biomass smoke-associated COPD and chronic bronchitis, 2004-2014. Chronic Obstr Pulm Dis. 2014;1(1):23–32. doi:10.15326/jcopdf.1.1.2013.000428848808
   PubMedGoogle Scholar